Use of a subcutaneous glucose sensor to detect decreases in glucose concentration prior to observation in blood

A Photoelectrochemical Sensor Based on Anodic TiO2 for Glucose Determination

A simple photoelectrochemical (PEC) sensor based on non-modified nanostructured anodic TiO₂ was fabricated and used for a rapid and sensitive detection of glucose. The anodic TiO₂ layers were synthesized in an ethylene glycol-based solution containing NH₄F (0.38 wt.%) and H₂O (1.79 wt.%) via a three-step procedure carried out at the constant voltage of 40 V at 20 °C. At the applied potentials of 0.2, 0.5, and 1 V vs. saturated calomel electrode (SCE), the developed sensor exhibited a photoelectochemical response toward the oxidation of glucose, and two linear ranges in calibration plots were observed. The highest sensitivity of 0.237 µA µmol⁻¹ cm⁻² was estimated for the applied bias of 1 V. The lowest limit of detection (LOD) was obtained for the potential of 0.5 V vs. SCE (7.8 mM) with the fastest response at ~3 s. Moreover, the proposed PEC sensor exhibited relatively high sensibility, good reproducibility, and due to its self-cleaning properties, a good long-term stability. Interfering tests showed the selective response of the sensor in the presence of urea and uric acid. Real-life sample analyses were performed using an intravenous glucose solution, which confirmed the possibility of determining the concentration of analyte in such types of samples.

Hydrogel optical fibers for continuous glucose monitoring

Continuous glucose monitoring facilitates the stringent control of blood glucose concentration in diabetic and intensive care patients. Optical fibers have emerged as an attractive platform; however, their practical applications are hindered due to lack of biocompatible fiber materials, complex and non-practical readout approaches, slow response, and time-consuming fabrication processes. Here, we demonstrate the quantification of glucose by smartphone-integrated fiber optics that overcomes existing technical limitations. Simultaneously, a glucose-responsive hydrogel was imprinted with an asymmetric microlens array and was attached to a multimode silica fiber's tip during photopolymerization, and subsequent interrogated for glucose sensing under physiological conditions. A smartphone and an optical power meter were employed to record the output signals. The functionalized fiber showed a high sensitivity (2.6 μW mM^-1), rapid response, and a high glucose selectivity in the physiological glucose range. In addition, the fiber attained the glucose complexation equilibrium within 15 min. The lactate interference was also examined and it was found minimal ∼0.1% in the physiological range. A biocompatible hydrogel made of polyethylene glycol diacrylate was utilized to fabricate a flexible hydrogel fiber to replace the silica fiber, and the fiber's tip was functionalized with the glucose-sensitive hydrogel during the ultraviolet light curing process. The biocompatible fiber was quickly fabricated by the molding, the readout approach was facile and practical, and the response to glucose was comparable to the functionalized silica fiber. The fabricated optical fiber sensors may have applications in wearable and implantable point-of-care and intensive-care continuous monitoring systems.

Detection of Human Plasma Glucose Using a Self-Powered Glucose Biosensor

This work presents the characterization of a self-powered glucose biosensor using individual sequential assays of human plasma glucose obtained from diabetic patients. The self-powered glucose biosensor is exploited to optimize the assay parameters for sensing plasma glucose levels. In particular, the biofuel cell component of the system at pH 7.4, 37 °C generates a power density directly proportional to plasma glucose and exhibited a maximum power density of 0.462 mW·cm−2 at a cell voltage of 0.213 V in 5 mM plasma glucose. Plasma glucose is further sensed by monitoring the charge/discharge frequency (Hz) of the integrated capacitor functioning as the transducer. With this method, the plasma glucose is quantitatively detected in 100 microliters of human plasma with unprecedented sensitivity, as high as 104.51 ± 0.7 Hz·mM−1·cm−2 and a detection limit of 2.31 ± 0.3 mM. The results suggest the possibility to sense human plasma glucose at clinically relevant concentrations without the use of an external power source.

The Facile Synthesis of Branch-Trunk Ag Hierarchical Nanostructures and Their Applications for High-Performance H₂O₂ Electrochemical Sensors

A novel branch-trunk Ag hierarchical nanostructure was synthesized via a galvanic replacement reaction combined with microwave-assisted synthesis using Te nanowire as a sacrificial template. The Te nanowire was synthesized via a hydrothermal process. We further investigated the potential application of the obtained hierarchical nanostructures in electrochemical sensor analysis. The results showed that the as-prepared sensor exhibited a wide linear range with 0.05 µM to 1.925 mM (R = 0.998) and the detection limit was estimated to be 0.013 µM (S/N = 3). These results indicate the branch-truck Ag hierarchical nanostructures are an excellent candidate material for sensing applications.

Ultrasound-enhanced transdermal delivery: recent advances and future challenges

The skin is a formidable diffusion barrier that restricts passive diffusion to small (<500 Da) lipophilic molecules. Methods used to permeabilize this barrier for the purpose of drug delivery are maturing as an alternative to oral drug delivery and hypodermic injections. Ultrasound can reversibly and non-invasively permeabilize the diffusion barrier posed by the skin. This review discusses the mechanisms of ultrasound-permeability enhancement, and presents technological innovations in equipment miniaturization and recent advances in permeabilization capabilities. Additionally, potentially exciting applications, including protein delivery, vaccination, gene therapy and sensing of blood analytes, are discussed. Finally, the future challenges and opportunities associated with the use of ultrasound are discussed. It is stressed that developing ultrasound for suitable applications is key to ensure commercial success.

Point accuracy and reliability of an interstitial continuous glucose-monitoring device in critically ill patients: a prospective study

Introduction

There is a need for continuous glucose monitoring in critically ill patients. The objective of this trial was to determine the point accuracy and reliability of a device designed for continuous monitoring of interstitial glucose levels in intensive care unit patients.

Methods

We evaluated point accuracy by comparing device readings with glucose measurements in arterial blood by using blood gas analyzers. Analytical and clinical accuracy was expressed in Bland-Altman plots, glucose prediction errors, and Clarke error grids. We used a linear mixed model to determine which factors affect the point accuracy. In addition, we determined the reliability, including duration of device start-up and calibration, skips in data acquisition, and premature disconnections of sensors.

Results

We included 50 patients in whom we used 105 sensors. Five patients from whom we could not collect the predefined minimum number of four consecutive comparative blood draws were excluded from the point accuracy analysis. Therefore, we had 929 comparative samples from 100 sensors in 45 patients (11 (7 to 28) samples per patient) during 4,639 hours (46 (27 to 134) hours per patient and 46 (21 to 69) hours per sensor) for the accuracy analysis. Point accuracy did not meet the International Organization for Standardization (ISO) 14971 standard for insulin dosing accuracy but did improve with increasing numbers of calibrations and was better in patients who did not have a history of diabetes. Out of 105 sensors, 60 were removed prematurely for a variety of reasons. The device start-up time was 49 (43 to 58) minutes. The number of skips in data acquisition was low, resulting in availability of real-time data during 95% (89% to 98%) of the connection time per sensor.

Conclusions

The point accuracy of a device designed for continuous real-time monitoring of interstitial glucose levels was relatively low in critically ill patients. The device had few downtimes, but one third of the sensors were removed prematurely because of unresolved sensor- or device-related problems.

Trial registration

Netherlands Trial Registry number: NTR3827. Registered 30 January 2013.

Electronic supplementary material

The online version of this article (doi:10.1186/s13054-015-0757-4) contains supplementary material, which is available to authorized users.

A pharmacokinetic model of a tissue implantable insulin sensor

While implantable sensors such as the continuous glucose monitoring system have been widely studied, both experimentally and mathematically, relatively little attention has been applied to the potential of insulin sensors. Such sensors can provide feedback control for insulin infusion systems and pumps and provide platforms for the monitoring of other biomarkers in vivo. In this work, the first pharmacokinetic model of an affinity sensor is developed for insulin operating subcutaneously in the limit of where mass transfer across biological membranes reaches a steady state. Using a physiological, compartmental model for glucose, insulin, and glucagon metabolism, the maximum sensor response and its delay time relative to plasma insulin concentration, are calculated based on sensor geometry, placement, and insulin binding parameters for a sensor localized within adipose tissue. A design relation is derived linking sensor dynamics to insulin time lag and placement within human tissue. The model should find utility in understanding dynamic insulin responses and forms the basis of model predictive control algorithms that incorporate sensor dynamics.

A colorimetric method of analysis for trace amounts of hydrogen peroxide with the use of the nano-properties of molybdenum disulfide

Molybdenum disulfide (MoS₂) with a layered structure was synthesized and applied for trace analysis of H₂O₂ in water based on a colorimetric method.

Accuracy evaluation of a new real-time continuous glucose monitoring algorithm in hypoglycemia

BACKGROUND

The purpose of this study was to evaluate the performance of a new continuous glucose monitoring (CGM) calibration algorithm and to compare it with the Guardian(®) REAL-Time (RT) (Medtronic Diabetes, Northridge, CA) calibration algorithm in hypoglycemia.

SUBJECTS AND METHODS

CGM data were obtained from 10 type 1 diabetes patients undergoing insulin-induced hypoglycemia. Data were obtained in two separate sessions using the Guardian RT CGM device. Data from the same CGM sensor were calibrated by two different algorithms: the Guardian RT algorithm and a new calibration algorithm. The accuracy of the two algorithms was compared using four performance metrics.

RESULTS

The median (mean) of absolute relative deviation in the whole range of plasma glucose was 20.2% (32.1%) for the Guardian RT calibration and 17.4% (25.9%) for the new calibration algorithm. The mean (SD) sample-based sensitivity for the hypoglycemic threshold of 70 mg/dL was 31% (33%) for the Guardian RT algorithm and 70% (33%) for the new algorithm. The mean (SD) sample-based specificity at the same hypoglycemic threshold was 95% (8%) for the Guardian RT algorithm and 90% (16%) for the new calibration algorithm. The sensitivity of the event-based hypoglycemia detection for the hypoglycemic threshold of 70 mg/dL was 61% for the Guardian RT calibration and 89% for the new calibration algorithm. Application of the new calibration caused one false-positive instance for the event-based hypoglycemia detection, whereas the Guardian RT caused no false-positive instances. The overestimation of plasma glucose by CGM was corrected from 33.2 mg/dL in the Guardian RT algorithm to 21.9 mg/dL in the new calibration algorithm.

CONCLUSIONS

The results suggest that the new algorithm may reduce the inaccuracy of Guardian RT CGM system within the hypoglycemic range; however, data from a larger number of patients are required to compare the clinical reliability of the two algorithms.

Can glucose be monitored accurately at the site of subcutaneous insulin delivery?

Because insulin promotes glucose uptake into adipocytes, it has been assumed that during measurement of glucose at the site of insulin delivery, the local glucose level would be much lower than systemic glucose. However, recent investigations challenge this notion. What explanations could account for a reduced local effect of insulin in the subcutaneous space? One explanation is that, in humans, the effect of insulin on adipocytes appears to be small. Another is that insulin monomers and dimers (from hexamer disassociation) might be absorbed into the circulation before they can increase glucose uptake locally. In addition, negative cooperativity of insulin action (a lower than expected effect of very high insulin concentrations)may play a contributing role. Other factors to be considered include dilution of interstitial fluid by the insulin vehicle and the possibility that some of the local decline in glucose might be due to the systemic effect of insulin. With regard to future research, redundant sensing units might be able to quantify the effects of proximity, leading to a compensatory algorithm. In summary, when measured at the site of insulin delivery, the decline in subcutaneous glucose level appears to be minimal, though the literature base is not large. Findings thus far support (1) the development of integrated devices that monitor glucose and deliver insulin and (2) the use of such devices to investigate the relationship between subcutaneous delivery of insulin and its local effects on glucose. A reduction in the number of percutaneous devices needed to manage diabetes would be welcome.

Interstitium versus Blood Equilibrium in Glucose Concentration and its Impact on Subcutaneous Continuous Glucose Monitoring Systems

The relationship between both interstitial and blood glucose remains a debated topic, on which there is still no consensus. The experimental evidence suggests that blood and interstitial fluid glucose levels are correlated by a kinetic equilibrium, which as a consequence has a time and magnitude gradient in glucose concentration between blood and interstitium. Furthermore, this equilibrium can be perturbed by several physiological effects (such as foreign body response, wound-healing effect, etc.), with a consequent reduction of interstitial fluid glucose versus blood glucose correlation. In the present study, the impact of operating in the interstitium on continuous glucose monitoring systems (CGMs) will be discussed in depth, both for the application of CGMs in the management of diabetes and in other critical areas, such as tight glycaemic control in critically ill patients.

Combination of hematin and PEDOT via 1-pyrenebutanoic acid: a new platform for direct electrochemistry of hematin and biosensing applications

In this work, we prepare a novel platform based on poly(3,4-ethylenedioxythiophene) (PEDOT) and 1-pyrenebutanoic acid (PBA). PEDOT is a conductive material of heteroatom doping, which can connect with PBA through π–π stacking.

Microdialysis-coupled enzymatic microreactor for in vivo glucose monitoring in rats

Continuous glucose monitoring (CGM) is an important aid for diabetic patients to optimize glycemic control and to prevent long-term complications. However, current CGM devices need further miniaturization and improved functional performance. We have coupled a previously described microfluidic chip with enzymatic microreactor (EMR) to a microdialysis probe and evaluated the performance of this system for monitoring subcutaneous glucose concentration in rats. Nanoliter volumes of microdialysis sample are efficiently reacted with continuously supplied glucose oxidase (GOx) solution in the EMR. The hydrogen peroxide produced is amperometrically detected at a (polypyrrole (PPy)-protected) thin-film Pt electrode. Subcutaneous glucose concentration was continuously monitored in anesthetized rats in response to intravenous injections of 20% glucose (w/v), 5 U/kg insulin, or saline as a control. In vitro evaluation showed a linear range of 2.1-20.6 mM and a sensitivity of 7.8 ± 1.0 nA/mM (n = 6). The physical lag time between microdialysis and the analytical signal was approximately 18 min. The baseline concentration of blood glucose was 10.2 ± 2.3 mM. After administering glucose to the rats, glucose levels increased by about 2 mM to 12.1 ± 2.3 mM in blood and 11.9 ± 1.5 mM in subcutaneous interstitial fluid (ISF). After insulin administration, glucose levels decreased by about 8 mM relative to baseline to 2.1 ± 0.6 mM in blood and 2.1 ± 0.9 mM in ISF. A microfluidic device with integrated chaotic mixer and EMR has been successfully combined with subcutaneous microdialysis to continuously monitor glucose in rats. This proof-of-principle demonstrates the feasibility of improved miniaturization in CGM based on microfluidics.

Continuous glucose monitoring: 40 years, what we've learned and what's next

After 40 years of research and development, today continuous glucose monitoring (CGM) is demonstrating the benefit it provides for millions with diabetes. To provide in vivo accuracy, new permselective membranes and mediated systems have been developed to prevent enzyme saturation and to minimize interference signals. Early in vivo implanted sensor research clearly showed that the foreign body response was a more difficult issue to overcome. Understanding the biological interface and circumventing the inflammatory response continue to drive development of a CGM sensor with accuracy and reliability performance suitable in a closed-loop artificial pancreas. Along with biocompatible polymer development, other complimentary algorithm and data analysis techniques have improved the performance of commercial systems significantly. For example, the mean average relative difference of Dexcom's CGM system improved from 26 to 14% and its use-life was extended from 3 to 7 d. Significant gains in usability, including size, flexibility, insertion, calibration, and data interface, have been incorporated into new generations of commercial CGM systems. Besides Medtronic, Dexcom, and Abbott, other major players are also investing in CGM. Becton Dickinson is conducting clinical trials with an optical galactose glucose binding system. Development of fully implanted sensor systems fulfills the desire for a discreet, reliable CGM system. Research continues to find innovative ways to help make living with diabetes easier and more normal, and new segments are being pursued (intensive care unit, surgery, behavior modification) in which CGM is being utilized.

The effect of rising vs. falling glucose level on amperometric glucose sensor lag and accuracy in Type 1 diabetes

BACKGROUND

Because declining glucose levels should be detected quickly in persons with Type 1 diabetes, a lag between blood glucose and subcutaneous sensor glucose can be problematic. It is unclear whether the magnitude of sensor lag is lower during falling glucose than during rising glucose.

METHODS

Initially, we analysed 95 data segments during which glucose changed and during which very frequent reference blood glucose monitoring was performed. However, to minimize confounding effects of noise and calibration error, we excluded data segments in which there was substantial sensor error. After these exclusions, and combination of data from duplicate sensors, there were 72 analysable data segments (36 for rising glucose, 36 for falling). We measured lag in two ways: (1) the time delay at the vertical mid-point of the glucose change (regression delay); and (2) determination of the optimal time shift required to minimize the difference between glucose sensor signals and blood glucose values drawn concurrently.

RESULTS

Using the regression delay method, the mean sensor lag for rising vs. falling glucose segments was 8.9 min (95%CI 6.1-11.6) vs. 1.5 min (95%CI -2.6 to 5.5, P<0.005). Using the time shift optimization method, results were similar, with a lag that was higher for rising than for falling segments [8.3 (95%CI 5.8-10.7) vs. 1.5 min (95% CI -2.2 to 5.2), P<0.001]. Commensurate with the lag results, sensor accuracy was greater during falling than during rising glucose segments.

CONCLUSIONS

In Type 1 diabetes, when noise and calibration error are minimized to reduce effects that confound delay measurement, subcutaneous glucose sensors demonstrate a shorter lag duration and greater accuracy when glucose is falling than when rising.

Is the response of continuous glucose monitors to physiological changes in blood glucose levels affected by sensor life?

BACKGROUND

None of the studies concerned with the performance of a continuous glucose monitor (CGM) over time has examined the extent to which extended periods of wear affect the responses of both CGM accuracy and lag time to rapid changes in blood glucose levels. Here we propose a novel approach to address these issues.

METHODS

Eight participants without diabetes were each fitted with two CGMs (Paradigm(®) 722 Real-Time [Medtronic, Northridge, CA]; abdominal and triceps regions) and completed fasted oral glucose challenges (OGCs) on six occasions over a 9-day period, while the CGMs were worn without removal. Arterialized blood samples were collected for comparison with CGM values.

RESULTS

There were marked mismatches and lag times between blood glucose and CGM values in response to all OGCs, most notably during the initial rapid increase in glucose levels. Abdominal and triceps CGMs consistently underestimated peak blood glucose by an average of 2.7±0.2 and 2.9±0.2 mM, respectively, and were associated with a peak blood glucose lag of 21.6±1.8 and 18.1±1.6 min, respectively. CGM accuracy did not deteriorate over 9 days of wear in OGCs for either the abdominal or triceps sensor. All participants found the triceps sensor site more comfortable than the abdominal site (P<0.05).

CONCLUSIONS

The current CGM sensor tested here may be used for extended periods, providing added economic benefits for the wearer. However, the marked inaccuracy and lag time of CGM readings when blood glucose levels change rapidly within the physiological range must be considered for optimal CGM use in glycemic management.

A multiple local models approach to accuracy improvement in continuous glucose monitoring

BACKGROUND

Continuous glucose monitoring (CGM) devices estimate plasma glucose (PG) from measurements in compartments alternative to blood. The accuracy of currently available CGM is yet unsatisfactory and may depend on the implemented calibration algorithms, which do not compensate adequately for the differences of glucose dynamics between the compartments. Here we propose and validate an innovative calibration algorithm for the improvement of CGM performance.

METHODS

CGM data from GlucoDay(®) (A. Menarini, Florence, Italy) and paired reference PG have been obtained from eight subjects without diabetes during eu-, hypo-, and hyperglycemic hyperinsulinemic clamps. A calibration algorithm based on a dynamic global model (GM) of the relationship between PG and CGM in the interstitial space has been obtained. The GM is composed by independent local models (LMs) weighted and added. LMs are defined by a combination of inputs from the CGM and by a validity function, so that each LM represents to a variable extent a different metabolic condition and/or sensor-subject interaction. The inputs best suited for glucose estimation were the sensor current I and glucose estimations Ĝ, at different time instants [I(k), I(k)(-1), Ĝ(k)(-1)] (IIG). In addition to IIG, other inputs have been used to obtain the GM, achieving different configurations of the calibration algorithm.

RESULTS

Even in its simplest configuration considering only IIG, the new calibration algorithm improved the accuracy of the estimations compared with the manufacturer's estimate: mean absolute relative difference (MARD)=10.8±1.5% versus 14.7±5.4%, respectively (P=0.012, by analysis of variance). When additional exogenous signals were considered, the MARD improved further (7.8±2.6%, P<0.05).

CONCLUSIONS

The LM technique allows for the identification of intercompartmental glucose dynamics. Inclusion of these dynamics into the calibration algorithm improves the accuracy of PG estimations.

Estimating plasma glucose from interstitial glucose: the issue of calibration algorithms in commercial continuous glucose monitoring devices

Evaluation of metabolic control of diabetic people has been classically performed measuring glucose concentrations in blood samples. Due to the potential improvement it offers in diabetes care, continuous glucose monitoring (CGM) in the subcutaneous tissue is gaining popularity among both patients and physicians. However, devices for CGM measure glucose concentration in compartments other than blood, usually the interstitial space. This means that CGM need calibration against blood glucose values, and the accuracy of the estimation of blood glucose will also depend on the calibration algorithm. The complexity of the relationship between glucose dynamics in blood and the interstitial space, contrasts with the simplistic approach of calibration algorithms currently implemented in commercial CGM devices, translating in suboptimal accuracy. The present review will analyze the issue of calibration algorithms for CGM, focusing exclusively on the commercially available glucose sensors.

Effect of short-term use of a continuous glucose monitoring system with a real-time glucose display and a low glucose alarm on incidence and duration of hypoglycemia in a home setting in type 1 diabetes mellitus

BACKGROUND

The objective of this study was to examine whether setting the low glucose alarm of a Guardian® REAL-Time continuous glucose monitoring system (CGMS) to 80 mg/dl for 3 days and providing instructions to users reduce the risk of hypoglycemia under free-living conditions in individuals with type 1 diabetes mellitus (T1DM).

METHODS

Fourteen participants with T1DM aged 26.1±6.0 years (mean±standard deviation) were fitted with a CGMS and assigned for 3 days to either an alarm [low and high blood glucose (BG) alarms set at 80 and 200 mg/dl, respectively] or no alarm condition, with each treatment administered to all participants following a counterbalanced design. All participants were given detailed instructions on how to respond appropriately to low glucose alarms.

RESULTS

The CGMS with alarm reduced the incidence of hypoglycemia (CGMS readings≤65 mg/dl) by 44% as well as the time spent below this hypoglycemic threshold by 64% without increasing average BG levels. However, the CGMS with alarm had no effect on the incidence of symptomatic hypoglycemia.

CONCLUSIONS

Short-term use of the CGMS with alarm, together with appropriate instructions for users, reduces the incidence and duration of hypoglycemia, but only to a limited extent, in part because it overestimates BG in the low glucose range.

Contribution of an intrinsic lag of continuous glucose monitoring systems to differences in measured and actual glucose concentrations changing at variable rates in vitro

BACKGROUND

Current continuous glucose monitoring (CGM) systems measure glucose levels in the interstitial fluid to estimate blood glucose concentration. A lag time has been observed between CGM system glucose readings and blood glucose levels when glucose levels are changing. Although this lag has been attributed to the time it takes glucose to equilibrate between blood and interstitial fluid compartments, it is unclear to what extent these inaccuracies reflect an intrinsic delay of the device itself.

METHODS

Four Guardian® REAL-Time CGM systems (CGMSs) (Medtronic Diabetes, Minimed, CA) and eight glucose sensors were tested in glucose solutions prepared in Krebs bicarbonate buffers at 37 °C. Glucose readings obtained from CGMSs were compared with actual glucose concentrations during controlled changes in glucose concentration performed at four rates (30, 90, and 220 mg/dl/hr(-1) and an instantaneous change of 110 mg/dl) using a linear gradient maker.

RESULTS

Irrespective of the rate and direction of changes in glucose concentration, the readings obtained from CGMSs were significantly different from actual glucose levels. The faster the rise or fall in actual glucose concentration, the more pronounced the mismatch with CGMS glucose readings. Furthermore, the intrinsic lag times (8.3 to 40.1 min) were high enough to account for the lags reported in previous in vivo studies.

CONCLUSIONS

The lag intrinsic of the CGMS may make a significant contribution to the mismatch between CGM system readings and blood glucose concentrations.

Accurate spectroscopic calibration for noninvasive glucose monitoring by modeling the physiological glucose dynamics

The physiological lag between blood and interstitial fluid (ISF) glucose is a major challenge for noninvasive glucose concentration measurements. This is a particular problem for spectroscopic techniques, which predominantly probe ISF glucose, creating inconsistencies in calibration, where blood glucose measurements are used as a reference. To overcome this problem, we present a dynamic concentration correction (DCC) scheme, based on the mass transfer of glucose between blood and ISF, to ensure consistency with the spectral measurements. The proposed formalism allows the transformation of glucose in the concentration domain, ensuring consistency with the acquired spectra in the calibration model. Taking Raman spectroscopy as a specific example, we demonstrate that the predicted glucose concentrations using the DCC-based calibration model closely match the measured glucose concentrations, while those generated with the conventional calibration methods show significantly larger deviations from the measured values. In addition, we provide an analytical formula for a previously unidentified source of limiting uncertainty arising in spectroscopic glucose monitoring from a lack of knowledge of glucose kinetics in prediction samples. A study with human volunteers undergoing glucose tolerance tests indicates that this lag uncertainty, which is comparable in magnitude to the uncertainty arising from noise and nonorthogonality in the spectral data set, can be reduced substantially by employing the DCC scheme in spectroscopic calibration.

Peak-time determination of post-meal glucose excursions in insulin-treated diabetic patients

OBJECTIVE

This study aimed to determine the optimal time to measure peak blood glucose values to find the best approach for self-monitoring blood glucose after a meal.

DESIGN AND METHODS

For this retrospective analysis, 69 ambulatory continuous glucose-monitoring system (CGMS) profiles were obtained from 75 consecutive insulin-treated patients with diabetes. The parameters measured were the peak post-meal blood glucose values, peak time, and rates of increase and decrease to and from the zenith of the resulting curves.

RESULTS

The mean peak time after breakfast was 72+/-23 min, which was reached in less than 90 min in 80% of the patients. The apparent glucose rate of increase from pre-meal to the maximum postprandial value was 1.23+/-0.76 mg/dL/min, while the glucose rate of decrease was 0.82+/-0.70 mg/dL/min. Peak time correlated with the amplitude of postprandial excursions, but not with the peak glucose value. Also, peak times were similar after breakfast, lunch and dinner, and in type 1 and type 2 diabetic patients.

CONCLUSION

To best assess peak postprandial glucose levels, the optimal time for blood glucose monitoring is about 1h and 15 min after the start of the meal, albeit with wide interpatient variability. Nevertheless, 80% of post-meal blood glucose peaks were observed at less than 90 min after the start of the meal.

Delays in minimally invasive continuous glucose monitoring devices: a review of current technology

Through the use of enzymatic sensors-inserted subcutaneously in the abdomen or ex vivo by means of microdialysis fluid extraction-real-time minimally invasive continuous glucose monitoring (CGM) devices estimate blood glucose by measuring a patient's interstitial fluid (ISF) glucose concentration. Signals acquired from the interstitial space are subsequently calibrated with capillary blood glucose samples, a method that has raised certain questions regarding the effects of physiological time lags and of the duration of processing delays built into these devices. The time delay between a blood glucose reading and the value displayed by a continuous glucose monitor consists of the sum of the time lag between ISF and plasma glucose, in addition to the inherent electrochemical sensor delay due to the reaction process and any front-end signal processing delays required to produce smooth traces. Presented is a review of commercially available, minimally invasive continuous glucose monitors with manufacturer reported device delays. The data acquisition process for the Medtronic MiniMed (Northridge, CA) continuous glucose monitoring system-CGMS Gold-and the Guardian RT monitor is described with associated delays incurred for each processing step. Filter responses for each algorithm are examined using in vitro hypoglycemic and hyperglycemic clamps, as well as with an analysis of fast glucose excursions from a typical meal response. Results demonstrate that the digital filters used by each algorithm do not cause adverse effects to fast physiologic glucose excursions, although nonphysiologic signal characteristics can produce greater delays.

A tale of two compartments: interstitial versus blood glucose monitoring

Self-monitoring of blood glucose was described as one of the most important advancements in diabetes management since the invention of insulin in 1920. Recent advances in glucose sensor technology for measuring interstitial glucose concentrations have challenged the dominance of glucose meters in diabetes management, while raising questions about the relationships between interstitial and blood glucose levels. This article will review the differences between interstitial and blood glucose and some of the challenges in measuring interstitial glucose levels accurately.

Glucose sensors: a review of current and emerging technology

Glucose monitoring technology has been used in the management of diabetes for three decades. Traditional devices use enzymatic methods to measure glucose concentration and provide point sample information. More recently continuous glucose monitoring devices have become available providing more detailed data on glucose excursions. In future applications the continuous glucose sensor may become a critical component of the closed loop insulin delivery system and, as such, must be selective, rapid, predictable and acceptable for continuous patient use. Many potential sensing modalities are being pursued including optical and transdermal techniques. This review aims to summarize existing technology, the methods for assessing glucose sensing devices and provide an overview of emergent sensing modalities.

Relationship between interstitial and blood glucose in type 1 diabetes patients: delay and the push-pull phenomenon revisited

BACKGROUND

Interpretation of glucose sensor results requires clarification of the relationship between interstitial (IG) and blood (BG) glucose. We examined the delay of IG upon BG change and reinvestigated the push-pull phenomenon in type 1 diabetes patients. The push-pull phenomenon postulates that IG shows a delayed increase but earlier decrease compared to BG. If so, postprandial sensor curves should have narrower peak widths than BG curves.

METHODS

For both sensors a two-point calibration procedure was used. Delay was assessed by shifting combined fitted postprandial glucose sensor curves horizontally. The sensor and BG peak widths of the separately fitted curves were assessed and compared. Peak width was re-assessed for the microdialysis sensor using raw current values to rule out any calibration effect on the shape of the curve. The contribution of instrumental delay to the earlier reported 7.1-min delay of the microdialysis sensor was calculated.

RESULTS

No delay [-2.2 +/- 6.2 (SD) min] was seen for the needle-type sensor. Instrumental delay was >6.2 min for the microdialysis sensor, accounting for more than 87% of the total reported delay of 7.1 +/- 5.5 min. Mean peak width for the BG curves was 100.8 +/- 25.0 min, for the needle-type sensor curves 110.0 +/- 20.5 min, and for the microdialysis sensor curves 104.6 +/- 21.7 min (P = 0.052 and P = 0.11 vs. BG, respectively). Mean peak width for the uncalibrated microdialysis current values was 105.0 +/- 23.1 min, which was not different from the peak width of the BG curves (P = 0.347).

CONCLUSIONS

IG-BG delay may be smaller than previously postulated. The sensor curves tended to have broader peaks than the BG curves, in contrast to the expected narrower peaks predicted by the push-pull phenomenon. This argues against the existence of the push-pull phenomenon.

Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans

BACKGROUND

These studies were designed to evaluate the accuracy of a microdialysis-based subcutaneous glucose sensor (GlucoDay, A. Menarini Diagnostics, Firenze, Italy) compared with a standard reference method of plasma glucose measurement during insulin-induced hypoglycemia.

RESEARCH DESIGN AND METHODS

Nine subjects without diabetes were studied in eu-, hypo-, and hyperglycemia (clamp technique). The GlucoDay was calibrated against one arterialized plasma glucose measurement (Glucose Analyzer, Beckman, Brea, CA), and plasma glucose estimates every 3 min were compared with paired plasma glucose values.

RESULTS

Accuracy of glucose estimates was not homogeneously distributed among subjects and depended on stability of the sensor's current signal during spontaneous euglycemia (R +/- -0.68). Linear regression analysis showed a good correlation between the two methods of measurement (R = 0.9), Deming regression showed the inclusion of the unit in the confidence interval of the slope (slope 0.95, 95% confidence interval 0.87-1.02), and the accuracy of the GlucoDay reached 40 +/- 15% (American Diabetes Association criteria). The mean relative difference was 6 +/- 8% in euglycemia, 13 +/- 14% during plasma glucose fall, 5 +/- 22% in the hypoglycemic plateau, and -14 +/- 16% during recovery from hypoglycemia. The Bland-Altman analysis indicated a bias of -1.9 +/- 16.6 mg/dL, whereas the Error Grid Analysis showed 94% of the Gluco- Day measurements in the acceptable zones of the grid. The time to reach the glycemic nadir was longer when measured with the GlucoDay (90 +/- 5 vs. 72.5 +/- 9 min, P < 0.05). However, absolute values of glycemic nadir, time spent in hypoglycemia, and the rate of fall of glycemia and the rate of recovery from the hypoglycemia were not statistically different.

CONCLUSIONS

GlucoDay closely monitors changes in plasma glucose before, during, and after hypoglycemia. However, these results can be achieved only if calibration of the GlucoDay is performed under conditions of sensor signal stability. Similar studies have to be performed in subjects with diabetes to validate the GlucoDay system.

Evaluation of a continuous glucose monitoring system for use in veterinary medicine

BACKGROUND

With the emergence of continuous glucose monitoring systems being used to provide a detailed glucose picture in humans, a commercially available system (CGMS(R), Medtronic Minimed, Northridge, CA) was examined for use in veterinary species.

METHODS

Adult, clinically normal horses (n = 7), cats (n = 3), dogs (n = 4), and cows (n = 5) were studied. Cats (n = 4), dogs (n = 5), and one horse with diabetes were included in the study. Several of the normal horses, including the horse with diabetes, and one cow were subjected to an intravenous glucose tolerance test. The CGMS was attached to each animal, and the recorded interstitial glucose concentrations were compared with whole blood glucose concentrations as determined by a point-of-care glucose meter. Events such as insulin administration, feeding, travel, or administration of intravenous glucose were all noted and compared with results from the CGMS.

RESULTS

There was a positive correlation between interstitial and whole blood glucose concentrations for all the clinically normal species, those with diabetes mellitus, and those receiving intravenous glucose. Events such as feeding, glucose or insulin administration, and transport to the clinic were noted by the owner or clinician and could be identified on the graph and correlated with time of occurrence.

CONCLUSIONS

Our data indicate that the use of the CGMS is valid for use in the species examined. Use of this system alleviated the need for multiple blood samples and the stress associated with obtaining those samples. This system may provide greater monitoring capabilities in patients with diabetes and promote the diagnostic and research potential of serial glucose monitoring in veterinary species.

Interstitial fluid glucose dynamics during insulin-induced hypoglycaemia

AIMS/HYPOTHESIS

Glucose sensors often measure s.c. interstitial fluid (ISF) glucose rather than blood or plasma glucose. Putative differences between plasma and ISF glucose include a protracted delay during the recovery from hypoglycaemia and an increased gradient during hyperinsulinaemia. These have often been investigated using sensor systems that have delays due to signal smoothing, or require long equilibration times. The aim of the present study was to define these relationships during hypoglycaemia in a well-equilibrated system with no smoothing.

METHODS

Hypoglycaemia was induced by i.v. insulin infusion (360 pmol.m(-2).min(-1)) in ten non-diabetic subjects. Glucose was sequentially clamped at approximately 5, 4.2 and 3.1 mmol/l and allowed to return to normoglycaemia. Subjects wore two s.c. glucose sensors (Medtronic MiniMed, Northridge, CA, USA) that had been inserted for more than 12 h. A two-compartment model was used to quantify the delay and gradient.

RESULTS

The delay during the fall in plasma glucose was not different from the delay during recovery (8.3+/-0.67 vs 6.3+/-1.1 min; p=0.27) and no differences were observed in the ratio of sensor current to plasma glucose at basal insulin (2.7+/-0.25 nA.mmol(-1).l) compared with any of the hyperinsulinaemic clamp phases (2.8+/-0.18, 2.7+/-0.021, 2.9+/-0.21; p=NS). The ratio was significantly elevated following recovery to normoglycaemia (3.1+/-0.2 nA.mmol(-1).l; p<0.001).

CONCLUSIONS/INTERPRETATION

The elevated ratio suggests that the plasma to ISF glucose gradient was decreased following hypoglycaemia, possibly due to increased skin blood flow. Recovery from hypoglycaemia is not accompanied by a protracted delay and insulin does not increase the plasma to s.c. ISF glucose gradient.

An implantable subcutaneous glucose sensor array in ketosis-prone rats: closed loop glycemic control

A closed loop system of diabetes control would minimize hyperglycemia and hypoglycemia. We therefore implanted and tested a subcutaneous amperometric glucose sensor array in alloxan-diabetic rats. Each array employed four sensing units, the outputs of which were processed in real time to yield a unified signal. We utilized a gain-scheduled insulin control algorithm which rapidly reduced insulin delivery as glucose concentration declined. Such a system was generally effective in controlling glycemia and the degree of lag between blood glucose and the sensor signal was usually 3-8 min. After prolonged implantation, this lag was sometimes longer, which led to impairment of sensor accuracy. Using a prospective two-point calibration method, sensor accuracy and closed loop control were good. A revised algorithm yielded better glycemic control than the initial algorithm did. Future research needs to further improve calibration methods and reduce foreign body fibrosis in order to avoid a time-related increase in lag duration.

Closed-loop insulin delivery – what lies between where we are and where we are going?

Closed-loop insulin delivery in individuals with diabetes can potentially lead to near-normal glucose profiles. To this end, existing subcutaneous glucose sensors and external insulin pumps can be linked with an insulin delivery algorithm to create a completely automated closed-loop system. This paper reviews current research into the development of such a system, with particular emphasis on creating a system emulating the physiological properties of the beta-cell. Issues related to using subcutaneous interstitial fluid for glucose sensing and insulin delivery are reviewed. Criteria for optimising the system are discussed using historical data. Existing strategies for open-loop pump therapy are presented with the objective of defining a path to advance from the existing physician/patient determined insulin therapy to a completely automated system.

Mediation ofin vivo glucose sensor inflammatory response via nitric oxide release

In vivo glucose sensor nitric oxide (NO) release is a means of mediating the inflammatory response that may cause sensor/tissue interactions and degraded sensor performance. The NO release (NOr) sensors were prepared by doping the outer polymeric membrane coating of previously reported needle-type electrochemical sensors with suitable lipophilic diazeniumdiolate species. The Clarke error grid correlation of sensor glycemia estimates versus blood glucose measured in Sprague-Dawley rats yielded 99.7% of the points for NOr sensors and 96.3% of points for the control within zones A and B (clinically acceptable) on Day 1, with a similar correlation for Day 3. Histological examination of the implant site demonstrated that the inflammatory response was significantly decreased for 100% of the NOr sensors at 24 h. The NOr sensors also showed a reduced run-in time of minutes versus hours for control sensors. NO evolution does increase protein nitration in tissue surrounding the sensor, which may be linked to the suppression of inflammation. This study further emphasizes the importance of NO as an electroactive species that can potentially interfere with glucose (peroxide) detection. The NOr sensor offers a viable option for in vivo glucose sensor development.

A novel approach to mitigating the physiological lag between blood and interstitial fluid glucose measurements

BACKGROUND

Lag between blood and interstitial fluid (ISF) glucose levels can contribute significantly to accuracy error in current and anticipated continuous glucose monitoring systems. Mitigating this physiological lag can be an important and useful means for improving the accuracy, and hence the clinical utility, of continuous glucose monitors.

METHODS

In a test of 22 subjects with diabetes in which a glucose excursion was induced through oral ingestion of a glucose load, glucose levels in finger blood and forearm dermal ISF were monitored over a 5-6-h period. ISF was sampled from two types of sites: sites at which local blood perfusion was elevated through modulated pressure application (test ISF), and control sites at which no perfusion elevation technique was employed (control ISF).

RESULTS

Average lag times (mean +/- SD values) between the two ISF samples and finger capillary blood glucose were determined to be 38.3 +/- 11.5 and 2.5 +/- 6.6 min, respectively, for the control and test ISF samples. Modulated pressure application mitigated the ISF physiological error by an average of 95% in this test.

CONCLUSIONS

The methodology presented here of using a pressure modulation technique to create an elevation in blood flow holds promise for significantly mitigating one of the most significant components of accuracy error for continuous monitoring systems.

Evaluation of a continuous glucose monitoring system for use in dogs, cats, and horses

OBJECTIVE

To evaluate a continuous glucose monitoring system (CGMS) for use in dogs, cats, and horses.

DESIGN

Prospective clinical study. Animals-7 horses, 3 cats, and 4 dogs that were clinically normal and 1 horse, 2 cats, and 3 dogs with diabetes mellitus.

PROCEDURE

Interstitial glucose concentrations were monitored and recorded every 5 minutes by use of a CGMS. Interstitial glucose concentrations were compared with whole blood glucose concentrations as determined by a point-of-care glucose meter. Interstitial glucose concentrations were also monitored in 2 clinically normal horses after oral and i.v. administration of glucose.

RESULTS

There was a positive correlation between interstitial and whole blood glucose concentrations for clinically normal dogs, cats, and horses and those with diabetes mellitus. Events such as feeding, glucose or insulin administration, restraint, and transport to the clinic were recorded by the owner or clinician and could be identified on the graph and associated with time of occurrence.

CONCLUSIONS AND CLINICAL RELEVANCE

Our data indicate that use of CGMS is valid for dogs, cats, and horses. This system alleviated the need for multiple blood samples and the stress associated with obtaining those samples. Because hospitalization was not required, information obtained from the CGMS provided a more accurate assessment of the animal's glucose concentrations for an extended period, compared with measurement of blood glucose concentrations. Use of the CGMS will promote the diagnostic and research potential of serial glucose monitoring.

In vivo calibration of the subcutaneous amperometric glucose sensors using a non-enzyme electrode

A new two-point calibration method for the subcutaneous amperometric continuous glucose sensor is reported. The proposed method is based on direct measurement of the background current (I(o)) using a non-enzyme electrode. For in vivo test, three electrodes were implanted in rabbits. Two of the three were identical needle-type enzyme electrodes with perfluorinated polymer outer layers (Pt/enzyme layer/Kel-F/PTFE/Kel-F/Nafion) that were placed in subcutaneous tissue and in a vessel (ear artery), respectively. And one non-enzyme electrode with exactly the same membrane composition as those of other two was in the subcutaneous layer to measure the background current. Implantation in the subcutaneous layer generated many crevices on the protecting layers of the electrodes. The signals from enzyme electrodes were effectively corrected by the measured background current from the non-enzyme electrode. In addition, a telemetric monitoring system was developed and evaluated for in vivo continuous glucose monitoring in order to alleviate the problems of motion artifact.

Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor

The objective of this study was to use a subcutaneous continuous glucose sensor to determine time differences in the dynamics of blood glucose and interstitial glucose. A total of 14 patients with type 1 diabetes each had two sensors (Medtronic/MiniMed CGMS) placed subcutaneously in the abdomen, acquiring data every 5 min. Blood glucose was sampled every 5 min for 8 h, and two liquid meals were given. A smoothing algorithm was applied to the blood glucose and interstitial glucose curves. The first derivatives of the glucose traces defined and quantified the timing of rises, peaks, falls, and nadirs. Altogether, 24 datasets were used for the analysis of time differences between interstitial and blood glucose and between sensors in each patient. Time differences between blood and interstitial glucose ranged from 4 to 10 min, with the interstitial glucose lagging behind blood glucose in 81% of cases (95% CIs 72.5 and 89.5%). The mean (+/-SD) difference between the two sensors in each patient was 6.7 +/- 5.1 min, representing random variation in sensor response. In conclusion, there is a time lag of interstitial glucose behind blood glucose, regardless of whether glycemia is rising or falling, but intersensor variability is considerable in this sensor system. Comparisons of interstitial and blood glucose kinetics must take statistical account of variability between sensors.